challenges of using sodium-glucose transporter-2 (sglt-2) inhibitors in the treatment of gestational diabetes and its safety considerations during pregnancy

sodium-glucose transporter-2 (sglt-2) inhibitors are a relatively new class of anti-diabetic drugs with potent effect in glycemic control and weight loss, as well as beneficial effects in the prevention and control of cardiac and renal complications in non-pregnant patients with type 2 diabetes. however, there is no enough clear and strong evidence about the beneficial or adverse effect of sglt-2 inhibitors usage during pregnancy for management of gestational diabetes (gdm) in human. this short letter discusses challenges in application of sglt-2 inhibitors in management of gdm.